Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
Coeptis Therapeutics Holdings (Nasdaq: COEP) has executed a Binding Letter of Intent to acquire NexGenAI Affiliates Network, a platform offering AI-powered marketing software and robotic process automation (RPA) capabilities. The acquisition aims to enhance Coeptis's operational efficiency while maintaining its focus on biopharmaceutical innovation. NexGenAI's suite of marketing tools utilizes AI and RPA to optimize campaigns, streamline workflows, and generate insights, particularly targeting the biotech, pharmaceutical, and multi-level marketing industries. The platform helps companies manage marketing campaigns while maintaining regulatory compliance.
Coeptis Therapeutics Holdings (Nasdaq: COEP) ha firmato una Lettera di Intenti Vincolante per acquisire la NexGenAI Affiliates Network, una piattaforma che offre software di marketing potenziato dall'IA e capacità di automazione dei processi robotici (RPA). L'acquisizione mira a migliorare l'efficienza operativa di Coeptis, mantenendo allo stesso tempo un focus sull'innovazione biopharma. La suite di strumenti di marketing di NexGenAI utilizza IA e RPA per ottimizzare le campagne, semplificare i flussi di lavoro e generare intuizioni, con particolare attenzione ai settori biotech, farmaceutico e del marketing multilivello. La piattaforma aiuta le aziende a gestire le campagne di marketing, mantenendo la conformità alle normative.
Coeptis Therapeutics Holdings (Nasdaq: COEP) ha ejecutado una Carta de Intención Vinculante para adquirir la NexGenAI Affiliates Network, una plataforma que ofrece software de marketing impulsado por IA y capacidades de automatización de procesos robóticos (RPA). La adquisición tiene como objetivo mejorar la eficiencia operativa de Coeptis, manteniendo su enfoque en la innovación biofarmacéutica. La suite de herramientas de marketing de NexGenAI utiliza IA y RPA para optimizar campañas, simplificar flujos de trabajo y generar información, particularmente dirigida a las industrias biotecnológica, farmacéutica y de marketing multinivel. La plataforma ayuda a las empresas a gestionar campañas de marketing mientras mantiene el cumplimiento regulatorio.
코엡티스 테라퓨틱스 홀딩스(Nasdaq: COEP)는 AI 기반 마케팅 소프트웨어와 로봇 프로세스 자동화(RPA) 기능을 제공하는 플랫폼인 넥스젠AI 제휴 네트워크를 인수하기 위한 구속력 있는 의향서를 체결했습니다. 이번 인수는 코엡티스의 운영 효율성을 향상시키는 것을 목표로 하며, 생명공학 제약 혁신에 대한 집중도를 유지합니다. 넥스젠AI의 마케팅 도구 모음은 AI와 RPA를 활용하여 캠페인을 최적화하고, 워크플로를 간소화하며, 특히 생명공학, 제약 및 다단계 마케팅 산업을 대상으로 통찰력을 생성합니다. 이 플랫폼은 기업이 마케팅 캠페인을 관리하도록 도와주며, 규제 준수를 유지합니다.
Coeptis Therapeutics Holdings (Nasdaq: COEP) a signé une Lettre d'Intention Engagée pour acquérir le NexGenAI Affiliates Network, une plateforme offrant des logiciels de marketing alimentés par l'IA et des capacités d'automatisation des processus robotiques (RPA). L'acquisition vise à améliorer l'efficacité opérationnelle de Coeptis tout en maintenant son attention sur l'innovation biopharmaceutique. La suite d'outils marketing de NexGenAI utilise l'IA et la RPA pour optimiser les campagnes, rationaliser les flux de travail et générer des insights, ciblant particulièrement les industries biotechnologique, pharmaceutique et de marketing à plusieurs niveaux. La plateforme aide les entreprises à gérer leurs campagnes marketing tout en garantissant la conformité réglementaire.
Coeptis Therapeutics Holdings (Nasdaq: COEP) hat ein Verbindliches Absichtsschreiben zur Übernahme des NexGenAI Affiliates Network unterzeichnet, einer Plattform, die KI-unterstützte Marketingsoftware und Möglichkeiten zur Automatisierung von Geschäftsprozessen (RPA) bietet. Die Übernahme zielt darauf ab, die operative Effizienz von Coeptis zu verbessern und gleichzeitig den Fokus auf biopharmazeutische Innovationen zu bewahren. NexGenAIs Suite von Marketing-Tools nutzt KI und RPA, um Kampagnen zu optimieren, Arbeitsabläufe zu straffen und Einblicke zu generieren, insbesondere in den Bereichen Biotechnologie, Pharmazie und Mehrstufenmarketing. Die Plattform hilft Unternehmen, Marketingkampagnen zu verwalten und gleichzeitig die Einhaltung von Vorschriften sicherzustellen.
- Acquisition expands company's technological capabilities through AI and RPA integration
- Creates new revenue opportunities in biotech, pharma, and MLM marketing sectors
- Enhances operational efficiency through automation tools
- Potential deviation from core biopharmaceutical business focus
- Integration costs and resources required for new technology implementation
Insights
The acquisition of NexGenAI Affiliates Network represents a strategic pivot for Coeptis, diversifying beyond its core biopharmaceutical focus into AI-powered marketing solutions. While the financial terms remain undisclosed, this move could create new revenue streams through marketing services for biotech and pharma companies. However, investors should note several concerns: 1) The departure from core business focus might dilute resources from drug development programs, 2) The company's small market cap of
The acquisition targets an AI marketing platform with RPA capabilities, but several technical aspects warrant scrutiny. The platform's actual technological capabilities, competitive advantages and integration readiness aren't detailed. While AI-powered marketing tools are valuable, the biotech/pharma marketing space is already served by established players with sophisticated compliance-focused solutions. The emphasis on MLM industry applications raises questions about the sophistication and scalability of the technology. Without proven deployment history or technical specifications, it's challenging to assess whether this represents genuine innovation or merely follows the current AI hype cycle.
The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth
NexGenAI has developed a suite of innovative marketing tools that utilize AI and RPA to optimize campaigns, streamline workflows, and generate actionable insights. By acquiring these assets, Coeptis will bring these state-of-the-art solutions to companies seeking to overcome marketing challenges in competitive and highly regulated sectors, particularly in the biotech, pharmaceutical and multi-level marketing ("MLM") industries. These tools will help companies run smarter, more efficient marketing campaigns, saving time and resources while staying compliant with strict regulations.
Dave Mehalick, President and CEO of Coeptis Therapeutics commented, "We are excited to integrate NexGenAI Affiliates Network and groundbreaking AI and RPA-driven tools into our offerings. In industries like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is critical."
Anshuman Dash, Lead Advisory behind the development of NexGenAI Affiliates Network commented, "The integration of NexGenAI's innovative AI-powered marketing solutions with Coeptis Therapeutics' forward-thinking approach marks a transformative step forward. This acquisition not only validates the cutting-edge technology we've developed but also aligns with Coeptis' mission to drive innovation in highly regulated industries. Together, we aim to revolutionize marketing strategies and operational efficiencies, ultimately delivering greater value to our partners and the industries we serve."
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of
About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned subsidiary NexGenAI Solutions Group, Inc., has developed a proprietary suite of advanced tools that power the NexGenAI Affiliates Network platform. These tools, featuring AI-driven marketing software and robotic process automation capabilities, are designed to optimize campaigns, streamline operations, and provide actionable, data-driven insights. NexGenAI's platform provides cutting-edge AI-driven solutions that revolutionize business operations across various sectors. By leveraging artificial intelligence, NexGenAI empowers companies to automate processes, optimize efficiency, and drive sustainable growth. For more information on NexgenAI go to nexgenai.io.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-executes-binding-letter-of-intent-to-acquire-ai-powered-marketing-solutions-for-biotech-pharmaceutical-and-other-industries-302320336.html
SOURCE Coeptis Pharmaceuticals, Inc.
FAQ
What is the purpose of Coeptis Therapeutics (COEP) acquiring NexGenAI Affiliates Network?
What technologies will COEP gain from the NexGenAI acquisition?